Breaking News Instant updates and real-time market news.

MGLN

Magellan Health

$70.85

5.8 (8.92%)

, CNC

Centene

$65.13

0.725 (1.13%)

12:49
02/20/19
02/20
12:49
02/20/19
12:49

Magellan Health buyout 'reasonable' up to $90 per share, says SVB Leerink

SVB Leerink analyst Ana Gupte says a takeout of Magellan Health (MGLN) "would be reasonable" up to $90 per share based on a sum-of-the-parts analysis. The stock in midday trading is up 10% to $71.28 after Reuters reported that the company is working with Goldman Sachs to gauge takeover interest. Activist hedge fund Starboard Value, which owns a 9.8% stake in Magellan, is likely to be pushing for a management shake-out, margin turnaround and eventual takeout by a strategic buyer such as Centene (CNC), Anthem (ANTM), UnitedHealth (UNH), WellCare (WCG) or Humana (HUM), Gupte tells investors in an intraday research note. The analyst suspects strategic buyers could pay a 25%-35% premium toward a takeout price of $90 to $95 per share post a margin turnaround. Gupte has a Market Perform rating on Magellan Health.

MGLN

Magellan Health

$70.85

5.8 (8.92%)

CNC

Centene

$65.13

0.725 (1.13%)

ANTM

Anthem

$312.20

0.5 (0.16%)

UNH

UnitedHealth

$269.44

-0.82 (-0.30%)

WCG

WellCare

$278.49

1.42 (0.51%)

HUM

Humana

$308.33

2.98 (0.98%)

MGLN Magellan Health
$70.85

5.8 (8.92%)

09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.
01/14/19
SPHN
01/14/19
INITIATION
Target $68
SPHN
Equal Weight
Magellan Health initiated with an Equal Weight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Magellan Health with an Equal Weight rating and $68 price target, citing what he calls its "disappointing fundamental execution" in 2018. While the emergence of an activist investor will likely increase accountability and urgency, he would wait for some initial signs of improving business trends before getting more constructive, Fidel tells investors.
11/13/18
LEER
11/13/18
DOWNGRADE
Target $70
LEER
Market Perform
Magellan Health downgraded to Market Perform from Outperform at Leerink
Leerink analyst Ana Gupte downgraded Magellan Health to Market Perform and lowered her price target for the shares to $70 from $90. The analyst says the stock has had "enormous challenges" since her upgrade, including the loss of the flagship serious mental ill contract in Florida. She believes "carve-out challenges could keep contract wins pressured in other states." Further, Magellan's margins do not look likely to normalize until late 2019 and or even 2020, Gupte tells investors in a research note.
11/28/18
JEFF
11/28/18
NO CHANGE
Target $79
JEFF
Buy
Jefferies sees Magellan turning Virginia around after Srivastava ouster
Jefferies analyst David Styblo believes Magellan Health's termination of Sam Srivastava, the CEO of its Healthcare division, shouldn't be too surprising given the challenges that business has had this year, particularly in the Virginia Medicaid start-up. Magellan CEO Barry Smith will take over and have a more direct role in improving performance, including spending time on the Virginia contract, Styblo tells investors in a research note. The analyst views the Virginia contract as a large opportunity and a key to realizing "significant" earnings power over the next few years. Styblo estimates the contract has $2.30 of earnings per share power from 2018. He thinks Magellan "can turn Virginia around" and keeps a Buy rating on the shares with a $79 price target.
CNC Centene
$65.13

0.725 (1.13%)

02/11/19
KEYB
02/11/19
NO CHANGE
Target $216
KEYB
Overweight
Workday price target raised to $216 from $179 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Workday (WDAY) to $216 from $179 on improving cloud growth prospects. The analyst notes that analysis of Key First Look Data: Jobs has exposed an unannounced F50 HCM win at UPS (UPS) that began hiring for the global HR transformation team in January. The data also exposed unannounced F100 HCM wins at Comcast (CMCSA; CMCSK), CapitalOne (COF), and Centene (CNC), although job dates suggest these deals may have closed in the October quarter. The January data also exposed a new cloud financials win at Adecco (AHEXY), Bracelin adds. The analyst reiterates an Overweight rating on Workday's shares.
02/06/19
OPCO
02/06/19
NO CHANGE
Target $83
OPCO
Outperform
Centene price target lowered to $83 from $165 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn lowered his price target for Centene to $83 from $165 to reflect split. The analyst notes that the company's Q4 results were solid, and its outlook remains strong, given the growth and stability of the ACA business, and the potential for $500M in savings over many years from the Centene Forward initiative. Given the strong prospects and attractive valuation, he reiterates an Outperform rating on the shares.
01/14/19
SPHN
01/14/19
INITIATION
Target $147
SPHN
Overweight
Centene initiated with an Overweight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Centene with an Overweight rating and $147 price target, citing the company's outlook for about 20% revenue and adjusted EPS growth in 2019, the potential near-term catalyst of the upcoming $6.4B North Carolina managed Medicaid contract award and the 17% pullback in the stock in the past 3 months.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $312
PIPR
Overweight
UnitedHealth positioned to outperform in 2019, says Piper Jaffray
Piper Jaffray analyst Sarah James said there "was so much focus" on UnitedHealth's (UNH) earnings call on its medical loss ratio, or MLR, that it pressured the stock early in the day, but she is not concerned. When accounting for adjustments and if one accounts for some Medicaid pressure, UnitedHealth had some improvement in MA or commercial, which could be positive for Humana (HUM) or Anthem (ANTM), according to James. UnitedHealth was also clear in post call conversation that Medicaid headwinds in 2018/19 were largely company specific, which James said leaves her feeling good heading into earnings from Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG). She reiterates her Overweight rating on UnitedHealth, as James sees potential for upside to her earnings estimates and believes the stock is positioned to outperform the group in 2019 as investors move to safer positions.
ANTM Anthem
$312.20

0.5 (0.16%)

01/31/19
RHCO
01/31/19
NO CHANGE
Target $340
RHCO
Hold
Anthem price target raised to $340 from $300 at SunTrust
SunTrust analyst David MacDonald raised his price target on Anthem to $340 after its Q4 earnings beat, saying the results were driven by "attractive core trends, stable Medicare cover ratio, ongoing efficiency initiatives and solid cash flows". The analyst also cites the company's strong 2019 guidance and acceleration of IngenioRx launch, but sees risk-reward as balanced given the competitive nature of the company commercial market.
01/31/19
MSCO
01/31/19
NO CHANGE
Target $391
MSCO
Overweight
Anthem price target raised to $391 from $372 at Morgan Stanley
Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating.
01/24/19
ARGS
01/24/19
INITIATION
Target $333
ARGS
Buy
Anthem initiated with a Buy at Argus
Argus initiated Anthem with a Buy and $333 price target.
01/31/19
LEHM
01/31/19
NO CHANGE
Target $330
LEHM
Overweight
Anthem price target raised to $330 from $305 at Barclays
Barclays analyst Steve Valiquette raised his price target for Anthem to $330 citing "high visibility" for 2019 and 2020 following the company's Q4 results. The analyst reiterates an Overweight rating on the shares.
UNH UnitedHealth
$269.44

-0.82 (-0.30%)

02/20/19
PIPR
02/20/19
NO CHANGE
Target $29
PIPR
Overweight
Tivity Health price target lowered to $29 from $44 at Piper Jaffray
Piper Jaffray analyst Sean Wieland lowered his price target for Tivity Health (TVTY) to $29 after accelerated insourcing by UnitedHealth (UNH) resulted in the company lowering its 2019 outlook. Recent checks with fitness clubs indicate that the process of transferring Silver Sneakers members to Renew Active by UnitedHealthcare is an administrative burden for the fitness clubs because they have to manually re-register the members, Wieland tells investors in a research note. Furthermore, the members must begin paying for the membership out of pocket, albeit at a 50% discount, adds the analyst. In addition, Wieland says he needs to see more evidence of revenue synergies to prove the rationale of Tivity's merger with Nutrisystem (NTRI). Nonetheless, the analyst keeps an Overweight rating on Tivity Health saying the stock is "too cheap."
02/15/19
JEFF
02/15/19
NO CHANGE
Target $93
JEFF
Hold
Jefferies views Quest selloff as overdone, but keeps Hold rating
Jefferies analyst Brian Tanquilut views the post-earnings selloff yesterday in shares of Quest Diagnostics as overdone. The analyst sees the company gaining share and driving volume growth this year as it gains UnitedHealth (UNH) market share, but he believes this is now baked into the stock. Management's guidance, while arguably more conservative than not, leaves little room for momentum-driving earnings upside surprises, Tanquilut tells investors in a research note. He lowered his price target for Quest to $93 from $96 and keeps a Hold rating on the name.
02/15/19
MZHO
02/15/19
NO CHANGE
Target $106
MZHO
Buy
Quest Diagnostics selloff yesterday a buying opportunity, says Mizuho
Mizuho analyst Ann Hynes recommends buying shares of Quest Diagnostics (DGX) following yesterday's 5% post-earnings selloff. The weakness related to confusion around not being a "preferred" in-network provider for UnitedHealth (UNH) currently and the initial 2019 guidance only setting a minimum range of "greater than $6.40" versus consensus of $6.56, Hynes tells investors in a research note. However, she thinks Quest "set the bar low to be able to beat and raise throughout the year." The analyst maintains a Buy rating on the shares with a $106 price target.
02/04/19
PIPR
02/04/19
NO CHANGE
PIPR
Overweight
Piper says UnitedHealth updated policy won't have real impact on Tandem revenue
Piper Jaffray analyst JP McKim said some will interpret UnitedHealth's (UNH) recently updated insulin pump policy, which expands Medtronic's (MDT) preferential agreement to patients age 7 and older, to mean that Tandem Diabetes (TNDM) "is farther away from getting back into good graces" with the insurer. However, while he understands that logic, McKim said he cannot know for sure either way and he thinks it won't have any real impact on Tandem's revenues. McKim, who keeps an Overweight rating on Tandem Diabetes shares, added that "patients and physicians hate this agreement as everyone wants open options for patients."
WCG WellCare
$278.49

1.42 (0.51%)

01/03/19
01/03/19
UPGRADE

Outperform
Follow-up: WellCare upgraded to Outperform following pullback at Wolfe Research
As previously reported, Wolfe Research upgraded WellCare to Outperform from Peer Perform. Analyst Justin Lake recommends taking advantage of the recent pullback and raised estimate to reflect the Aetna PDP acquisition and Medicaid margin improvement. Lake lowered WellCare's price target to $263 from $293, but said the company offers unique earnings growth visibility and potential upside to estimates in several areas including capital deployment and optionality should the company win a large Medicaid contract management has acknowledged bidding on.
02/06/19
BMOC
02/06/19
NO CHANGE
Target $330
BMOC
Outperform
WellCare price target raised to $330 from $287 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on WellCare to $330 and kept his Outperform rating after its Q4 earnings beat. The analyst cites the management's confidence in the company's "multiple levers for earnings growth through 20201", adding that WellCare is also among the "best-positioned growth stories in Managed Care" given its "modest" size and "significant room" for margin expansion.
01/14/19
SPHN
01/14/19
INITIATION
Target $276
SPHN
Overweight
WellCare initiated with an Overweight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started WellCare with an Overweight rating and $276 price target. He sees the key growth event for Medicaid in 2019 being the $6.4B North Carolina RFP contract awards in February and lists WellCare as among the companies that could win contracts.
HUM Humana
$308.33

2.98 (0.98%)

01/14/19
SPHN
01/14/19
INITIATION
Target $336
SPHN
Overweight
Humana initiated with an Overweight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Humana with an Overweight rating and $336 price target, stating that it has the most earnings leverage to the Medicare Advantage market, which he identifies as having the strongest long-term growth outlook among all healthcare payer end markets. Fidel also notes that Humana shares have pulled back about 16% in the past 3 months.
02/07/19
FBCO
02/07/19
NO CHANGE
Target $352
FBCO
Outperform
Humana price target lowered to $352 from $390 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Humana to $352 from $390 given the lack of visibility of HIF moratorium extension. The analyst reiterates an Outperform rating on the shares.
01/11/19
01/11/19
UPGRADE
Target $372

Outperform
Humana upgraded to Outperform on pullback, improving outlook at Cowen
As previously reported, Cowen analyst Charles Rhyee upgraded Humana to Outperform from Market Perform, noting that the company revised up its net membership growth estimate for its individual MA products for 2019 at the end of November and then bumped it up again more recently. Rhyee raised his 2019 estimates for Humana, adding that he sees room for additional upside given the company's room to lever up to fund M&A or share buybacks. Additionally, the pullback in shares this past fall seems to have removed a premium for a potential takeout, which he does not think was warranted given the lack of likely buyers, Rhyee said. He maintains a $372 price target on Humana shares.

TODAY'S FREE FLY STORIES

TBIO

Translate Bio

$11.01

0.405 (3.82%)

21:06
09/17/19
09/17
21:06
09/17/19
21:06
Syndicate
Translate Bio 9M share Spot Secondary priced at $10.00 »

Citi, Jefferies and SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SWK

Stanley Black & Decker

$144.45

0.73 (0.51%)

21:05
09/17/19
09/17
21:05
09/17/19
21:05
Downgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LEN

Lennar

$53.10

-0.23 (-0.43%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Lennar rating change  »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

WHR

Whirlpool

$152.15

3.4 (2.29%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Whirlpool rating change  »

Whirlpool downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary  »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.85

0.08 (0.15%)

18:25
09/17/19
09/17
18:25
09/17/19
18:25
Periodicals
Total CEO says Saudi oil facility strikes will have consequences, Reuters says »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SMMF

Summit Financial Group

$25.96

-0.29 (-1.10%)

18:02
09/17/19
09/17
18:02
09/17/19
18:02
Hot Stocks
Summit Financial and Cornerstone Financial sign merger agreement »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$30.93

-0.89 (-2.80%)

18:01
09/17/19
09/17
18:01
09/17/19
18:01
Earnings
Steel Dynamics sees Q3 EPS 66c-70c, consensus 71c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

18:00
09/17/19
09/17
18:00
09/17/19
18:00
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says FY21 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.